Jun Gong, MD

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).